Results 131 to 140 of about 30,070 (260)

Pseudotumor Cerebri Syndrome and Essential Thrombocythemia: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Pseudotumor cerebri syndrome (PTCS) is characterized by elevated intracranial pressure in the absence of intracranial mass lesions, structural abnormalities, or infectious conditions. Although the exact pathogenesis of PTCS remains largely elusive, it is increasingly recognized as a multifactorial condition.
Fang‐Tzu Chang   +2 more
wiley   +1 more source

Acute Finger Ischemia Evaluated With Point‐Of‐Care‐Ultrasound and Diagnosed With Concurrent Polycythemia Vera, Antiphospholipid Syndrome, and Tobacco Use

open access: yesClinical Case Reports, Volume 14, Issue 6, June 2026.
We present a case of digital ischemia investigated and localized using point‐of‐care ultrasound (POCUS), in a patient that was subsrquently diagnosed with antiphospholipid syndrome and polycythemia vera concurrently, in the setting of active tobacco use. ABSTRACT In patients with undifferentiated extremity ischemia, point‐of‐care ultrasound (POCUS) can
Tristan Burgess   +2 more
wiley   +1 more source

When Chronic Pain Clouds Acute Diagnosis: Femoral Shaft Osteonecrosis With Superimposed Pseudomonas Osteomyelitis in a Medically Complex Patient

open access: yesClinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT In medically complex patients with chronic pain, new or worsening symptoms should prompt careful reassessment. Avascular necrosis, particularly in the setting of prolonged steroid use, may be overlooked due to diagnostic overshadowing. Timely recognition requires multidisciplinary collaboration and vigilance to distinguish acute pathology from
Ji‐Hoon Lee   +3 more
wiley   +1 more source

Adverse Prognostic Impact of Pretransplant Serum Ferritin and Hepcidin on Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation

open access: yes
American Journal of Hematology, Volume 101, Issue 6, Page 1239-1243, June 2026.
Michelle Pirotte   +6 more
wiley   +1 more source

Cytokine receptor and JAK/STAT pathway mutations in acute myeloid leukemia: Prevalence and clinical impact

open access: yesCancer, Volume 132, Issue 11, 1 June 2026.
Abstract Background Mutations in cytokine receptor and JAK/STAT; Cy‐JAK/STAT) signaling genes drive myeloproliferative neoplasms (MPNs) but remain incompletely characterized in acute myeloid leukemia (AML). The authors evaluated the prevalence, clinical presentation, and prognostic significance of Cy‐JAK/STAT pathway mutations in patients with AML and ...
Moath Albliwi   +22 more
wiley   +1 more source

Impact of Frontline Treatment Strategies on Outcomes in Patients With Acute Myeloid Leukemia, Myelodysplasia‐Related

open access: yesCancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background The 5th edition of the World Health Organization (WHO) classification updated the term for acute myeloid leukemia with myelodysplasia‐related changes (AML‐MRC) to acute myeloid leukemia, myelodysplasia‐related (AML‐MR), along with new diagnostic criteria.
Yi Li   +10 more
wiley   +1 more source

Genetic Variants of BMI1 (rs1042059 and rs11591377) and Their Potential Role in Leukemia Susceptibility: A Narrative Review

open access: yesHealth Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background and Aims Leukemia is a heterogeneous group of hematologic malignancies influenced by both genetic and environmental factors. The B‐cell‐specific Moloney murine leukemia virus integration site 1 (BMI1) gene, a key regulator of hematopoietic stem cell self‐renewal and oncogenesis, has been implicated in leukemia pathogenesis.
Mojtaba Aghaei   +2 more
wiley   +1 more source

Calreticulin Type 26 Mutation in Myelofibrosis: A Rare Variant With Diagnostic Challenges

open access: yesJournal of Clinical Laboratory Analysis, Volume 40, Issue 11, June 2026.
ABSTRACT Background Myeloproliferative neoplasms (MPNs) are clonal hematologic disorders commonly driven by mutations in JAK2, MPL, or CALR. Because routine CALR assays are largely optimized for the canonical Type 1 and Type 2 exon 9 variants, rare noncanonical mutations may be missed, creating diagnostic challenges.
Teresa Maltese   +6 more
wiley   +1 more source

Single‐Agent Selinexor Versus Physician's Choice in Previously Treated Myelofibrosis: Results From the Phase 2 XPORT‐035 Study

open access: yeseJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Background Janus kinase inhibitors (JAKis), the current standard of care for myelofibrosis (MF), provide clinical benefit, but responses are frequently incomplete, non‐durable, and associated with cytopenias, underscoring the need for therapies with novel mechanisms of action.
Sebastian Grosicki   +15 more
wiley   +1 more source

Circulating CD117+/CD34+/CD45dim Myeloblasts as Biomarkers of Disease Activity in Primary Myelofibrosis—A Pilot Study

open access: yeseJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Introduction Clinical benefit measures and surrogates for leukaemic transformation or overall survival are scarce in MF. Circulating myeloblast (CMB) counts have the biological plausibility to indicate disease evolution, but they are still determined by an outdated approach with microscopic examination and fixed cut‐offs.
Malak Tamer Abdelmaksoud   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy